Carl Sellars
Physician Assistant · Orlando, FLNPI 1891765855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 541 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,627, 2.3 times the $1,568 reported in 2021. Among physician assistant clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 541 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Sanofi$697
- AbbVie$620
- Amgen$567
- Takeda Pharmaceuticals U.S.A., Inc.$503
- plus $6K from 43 others
What the payments were for
- Food & beverage$10,712100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,746 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $24,470 |
| JardianceEmpagliflozin | 11 | $6,253 |
| SynthroidLevothyroxine Sodium | 14 | $1,464 |
| Pantoprazole Sodium | 50 | $1,182 |
| Levothyroxine Sodium | 77 | $839 |
| Metoprolol Succinate | 54 | $798 |
| Rosuvastatin Calcium | 46 | $736 |
| Montelukast Sodium | 41 | $685 |
| Omeprazole | 39 | $628 |
| Atorvastatin Calcium | 75 | $601 |
| Simvastatin | 36 | $562 |
| Alprazolam | 86 | $508 |
| Amlodipine Besylate | 68 | $426 |
| Losartan Potassium | 46 | $426 |
| Metformin Hcl | 43 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $453 | $24,47024 claims |
| AbbVieSynthroid | $620 | $1,46414 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $64 | $83977 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Orlando
- Risha BellomoOrlando$397K
- Nicole HillOrlando$319K
- Gina ManginOrlando$300K
- Brandon NievesOrlando$235K
- Nancy MimbsOrlando$118K
- Daniel HendricksOrlando$53K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.